Publication | Closed Access

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

5-Year AnalysisBreast OncologyOncologyHealth SciencesClinical TrialsImmune Checkpoint InhibitorBreast CancerPharmacotherapyTrastuzumab-based Adjuvant TherapyCancer TreatmentMedicineRadiation OncologyHer2-positive Breast Cancer